Nutex Health (NUTX) issues Q3 2025 earnings press release Exhibit

Rhea-AI Filing Summary

Nutex Health Inc. (NUTX) reported that it has released its financial and operating results for the third quarter ended September 30, 2025. The company announced these results on November 19, 2025 and made them available through a press release.

The press release is furnished as Exhibit 99.1 to this current report on Form 8-K, and is designated as furnished rather than filed under securities laws, meaning it is not automatically incorporated into other securities offerings or filings unless expressly stated.

Insights

Equity disclosure analyst

Nutex Health announces Q3 2025 results via furnished press release.

Nutex Health Inc. has issued its financial and operating results for the quarter ended September 30, 2025, communicating them through a press release furnished on November 19, 2025. The Form 8-K serves mainly as a notification and delivery mechanism for that information.

The company characterizes Item 2.02 information, including Exhibit 99.1, as "furnished" rather than "filed" under the Exchange Act and not automatically incorporated into Securities Act registration statements. This is a common approach for earnings materials and limits the applicability of certain liability provisions.

For investors, the substantive details about revenue, earnings, and operating trends reside in the press release itself. Subsequent periodic reports, such as the Form 10-Q covering the quarter ended September 30, 2025, will typically provide more comprehensive financial statements and management discussion consistent with these announced results.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

0001479681FALSE00014796812025-11-182025-11-18

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported) November 19, 2025

NUTEX HEALTH INC.

(Exact name of registrant as specified in its charter)

Delaware			001-41346			11-3363609
(State or Other Jurisdiction of Incorporation)			(Commission File Number)			(I.R.S. Employer Identification Number)

6030 S. Rice Ave, Suite C, Houston, Texas 77081

(Address of principal executive offices) (zip code)

(713) 660-0557

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o   Precommencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o   Precommencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class			Trading Symbols(s)			Name of each exchange on which registered
Common Stock, $0.001 par value			NUTX			NASDAQ Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company o

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Item 2.02. Results of Operations and Financial Condition

On November 19, 2025, Nutex Health Inc. (the “Company”) announced its financial and operating results for the third quarter ending September 30, 2025. A copy of the Company’s press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

Item 9.01 Financial Statements and Exhibits

(d)Exhibits

Exhibit No.			Description of Exhibit
99.1			Press Release dated November 19, 2025
104			Cover Page Interactive Data File - the cover page interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.

THE INFORMATION CONTAINED IN ITEM 2.02 OF THIS CURRENT REPORT, INCLUDING EXHIBIT 99.1 ATTACHED HERETO, SHALL NOT BE DEEMED “FILED” FOR THE PURPOSES OF SECTION 18 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, NOR SHALL IT BE DEEMED INCORPORATED BY REFERENCE INTO ANY REGISTRATION STATEMENT OR OTHER FILING PURSUANT TO THE SECURITIES ACT OF 1933, AS AMENDED, EXCEPT AS OTHERWISE EXPRESSLY STATED IN SUCH FILING

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: November 19, 2025

Nutex Health Inc.

By: /s/ Jon C. Bates

Jon C. Bates

Chief Financial Officer

FAQ

What did Nutex Health Inc. (NUTX) announce in this Form 8-K?

Nutex Health Inc. announced that it has released its financial and operating results for the third quarter ended September 30, 2025, as stated in Item 2.02.

How did Nutex Health (NUTX) provide its Q3 2025 financial results?

The company provided its Q3 2025 financial and operating results through a press release furnished as Exhibit 99.1 to this Form 8-K.

On what date did Nutex Health release its Q3 2025 results?

Nutex Health announced its third quarter 2025 results on November 19, 2025, which is the date of the press release and the report date for this Form 8-K.

Are Nutex Healths Q3 2025 results considered filed with the SEC?

The company states that the information in Item 2.02 and Exhibit 99.1 is furnished, not filed, and is not deemed incorporated into Securities Act registration statements unless expressly stated.

Where can investors find more detail on Nutex Healths Q3 2025 performance?

More detailed information is contained in the press release dated November 19, 2025, which is attached as Exhibit 99.1 to this Form 8-K.

Who signed the Nutex Health (NUTX) Form 8-K for the Q3 2025 results?

The Form 8-K was signed on behalf of Nutex Health Inc. by Jon C. Bates, Chief Financial Officer, dated November 19, 2025.